Department of Urology, Konstantopouleion-Patision Hospital, N. Ionia, 14233 Attika, Greece.
Department of Molecular Biology and Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Int J Mol Sci. 2024 Oct 4;25(19):10704. doi: 10.3390/ijms251910704.
Diabetic bladder dysfunction (DBD) comprises a wide spectrum of lower urinary tract symptoms that impact diabetic patients' lives, including urinary frequency, urgency, incontinence, and incomplete bladder emptying. To relieve symptoms, anticholinergics have been widely prescribed and are considered an effective treatment. There is increasing evidence that diabetic patients may benefit from the use of phosphodiesterase 5 (PDE5) inhibitors. This narrative review aims to provide a brief overview of the pathophysiology of DBD along with a focus on cholinergic and phosphodiesterase inhibitors as therapies that benefit DBD. An examination of the literature suggests compelling avenues of research and underscores critical gaps in understanding the mechanisms underlying DBD. New tools and models, especially rodent models, are required to further elucidate the mechanisms of action of current therapies in the treatment of DBS.
糖尿病膀胱功能障碍（DBD）包括一系列影响糖尿病患者生活的下尿路症状，包括尿频、尿急、尿失禁和膀胱排空不全。为了缓解症状，抗胆碱能药物被广泛应用，并被认为是一种有效的治疗方法。越来越多的证据表明，糖尿病患者可能受益于使用磷酸二酯酶 5（PDE5）抑制剂。本综述旨在简要概述 DBD 的病理生理学，并重点关注胆碱能和磷酸二酯酶抑制剂作为治疗 DBD 的方法。对文献的研究表明，有令人信服的研究途径，并强调了对 DBD 潜在机制理解的关键差距。需要新的工具和模型，特别是啮齿动物模型，以进一步阐明当前治疗 DBS 的治疗方法的作用机制。
